BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhu Q, Li N, Zeng X, Han Q, Li F, Yang C, Lv Y, Zhou Z, Liu Z. Hepatocellular carcinoma in a large medical center of China over a 10-year period: evolving therapeutic option and improving survival. Oncotarget. 2015;6:4440-4450. [PMID: 25686836 DOI: 10.18632/oncotarget.2913] [Cited by in Crossref: 38] [Cited by in F6Publishing: 45] [Article Influence: 5.4] [Reference Citation Analysis]
Number Citing Articles
1 Ma YY, Zhang GH, Li J, Wang SB, Hu ZM, Zhang CW, Li E. The correlation of NLRC3 expression with the progression and prognosis of hepatocellular carcinoma. Hum Pathol. 2018;82:273-281. [PMID: 30081150 DOI: 10.1016/j.humpath.2018.07.031] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
2 Ren F, Zhang J, Gao Z, Zhu H, Chen X, Liu W, Xue Z, Gao W, Wu R, Lv Y, Hu L. Racial disparities in the survival time of patients with hepatocellular carcinoma and intrahepatic cholangiocarcinoma between Chinese patients and patients of other racial groups: A population-based study from 2004 to 2013. Oncol Lett 2018;16:7102-16. [PMID: 30546445 DOI: 10.3892/ol.2018.9550] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
3 Li S, Yao J, Xie M, Liu Y, Zheng M. Exosomal miRNAs in hepatocellular carcinoma development and clinical responses. J Hematol Oncol 2018;11:54. [PMID: 29642941 DOI: 10.1186/s13045-018-0579-3] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 6.3] [Reference Citation Analysis]
4 Han Q, Deng H, Fan X, Wang X, Zhang X, Zhang K, Li N, Lv Y, Liu Z. Increased Serum Pentraxin 3 Levels are Associated with Poor Prognosis of Hepatitis B Virus-Related Hepatocellular Carcinoma. J Hepatocell Carcinoma 2021;8:1367-73. [PMID: 34805015 DOI: 10.2147/JHC.S337936] [Reference Citation Analysis]
5 Ma Z, Huang H, Xu Y, He X, Wang J, Hui B, Ji H, Zhou J, Wang K. Current advances of long non-coding RNA highly upregulated in liver cancer in human tumors. Onco Targets Ther 2017;10:4711-7. [PMID: 29026319 DOI: 10.2147/OTT.S136915] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
6 Ju G, Zhou T, Zhang R, Pan X, Xue B, Miao S. DUSP12 regulates the tumorigenesis and prognosis of hepatocellular carcinoma. PeerJ 2021;9:e11929. [PMID: 34414037 DOI: 10.7717/peerj.11929] [Reference Citation Analysis]
7 Zhu Q, Li N, Li F, Sang J, Deng H, Han Q, Lv Y, Li C, Liu Z. Association of LTBR polymorphisms with chronic hepatitis B virus infection and hepatitis B virus-related hepatocellular carcinoma. Int Immunopharmacol 2017;49:126-31. [PMID: 28575727 DOI: 10.1016/j.intimp.2017.05.031] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
8 Wang T, Lu XJ, Chi JC, Ding M, Zhang Y, Tang XY, Li P, Zhang L, Zhang XY, Zhai B. Microwave ablation of hepatocellular carcinoma as first-line treatment: long term outcomes and prognostic factors in 221 patients. Sci Rep 2016;6:32728. [PMID: 27620527 DOI: 10.1038/srep32728] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
9 He H, Wang Y, Ye P, Yi D, Cheng Y, Tang H, Zhu Z, Wang X, Jin S. Long noncoding RNA ZFPM2-AS1 acts as a miRNA sponge and promotes cell invasion through regulation of miR-139/GDF10 in hepatocellular carcinoma. J Exp Clin Cancer Res 2020;39:159. [PMID: 32795316 DOI: 10.1186/s13046-020-01664-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
10 Dong J, Zhu Y, Ma F, Ren Y, Lu J, Wang Z, Qin L, Wu R, Lv Y. Conditional disease-free survival after liver transplantation for hepatocellular carcinoma: A two-center experience. Medicine (Baltimore) 2016;95:e4383. [PMID: 27495049 DOI: 10.1097/MD.0000000000004383] [Cited by in Crossref: 5] [Article Influence: 1.0] [Reference Citation Analysis]
11 Li Z, Li N, Li F, Zhou Z, Sang J, Jin Z, Liu H, Han Q, Lv Y, Liu Z. Genetic polymorphisms of immune checkpoint proteins PD-1 and TIM-3 are associated with survival of patients with hepatitis B virus-related hepatocellular carcinoma. Oncotarget 2016;7:26168-80. [PMID: 27034168 DOI: 10.18632/oncotarget.8435] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
12 Fu H, Zhang Y, Chen J, Zhou B, Chen G, Chen P. Tmub1 Suppresses Hepatocellular Carcinoma by Promoting the Ubiquitination of ΔNp63 Isoforms. Mol Ther Oncolytics 2020;18:126-36. [PMID: 32671188 DOI: 10.1016/j.omto.2020.06.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
13 Bei C, Zhang Y, Wei R, Zhu X, Wang Z, Zeng W, Chen Q, Tan S. Clinical significance of CMTM4 expression in hepatocellular carcinoma. Onco Targets Ther 2017;10:5439-43. [PMID: 29180877 DOI: 10.2147/OTT.S149786] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 3.2] [Reference Citation Analysis]
14 Fu H, Zhang Y, Chen Y, Chen J, Chen P. CSN1 facilitates proliferation and migration of hepatocellular carcinoma cells by upregulating cyclin A2 expression. Mol Med Rep 2021;23:46. [PMID: 33200803 DOI: 10.3892/mmr.2020.11684] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Chen F, Wang N, Tan HY, Guo W, Zhang C, Feng Y. The functional roles of exosomes-derived long non-coding RNA in human cancer. Cancer Biol Ther 2019;20:583-92. [PMID: 30739532 DOI: 10.1080/15384047.2018.1564562] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
16 Deng H, Fan X, Wang X, Zeng L, Zhang K, Zhang X, Li N, Han Q, Lv Y, Liu Z. Serum pentraxin 3 as a biomarker of hepatocellular carcinoma in chronic hepatitis B virus infection. Sci Rep 2020;10:20276. [PMID: 33219288 DOI: 10.1038/s41598-020-77332-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 Qiu B, Zhao MF, Yue ZD, Zhao HW, Wang L, Fan ZH, He FL, Dai S, Yao JN, Liu FQ. Combined transjugular intrahepatic portosystemic shunt and other interventions for hepatocellular carcinoma with portal hypertension. World J Gastroenterol 2015; 21(43): 12439-12447 [PMID: 26604651 DOI: 10.3748/wjg.v21.i43.12439] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
18 Zhu Q, Li N, Li F, Zhou Z, Sang J, Zeng X, Han Q, Lv Y, Zhao W, Liu Z. How admissions to various medical specialty divisions determines the outcome of patients with hepatocellular carcinoma: results from a retrospective study in a large hospital of northwest China. Ther Clin Risk Manag 2017;13:545-53. [PMID: 28458557 DOI: 10.2147/TCRM.S131290] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
19 Li Q, Xiong DL, Wang H, Jin WL, Ma YY, Fan XM. High Expression of SLC41A3 Correlates with Poor Prognosis in Hepatocellular Carcinoma. Onco Targets Ther 2021;14:2975-88. [PMID: 33981147 DOI: 10.2147/OTT.S296187] [Reference Citation Analysis]
20 Sasa GBK, Xuan C, Lyu G, Ding X, Meiyu F. Long Non-coding RNA ZFPM2-AS1: A Novel Biomarker in the Pathogenesis of Human Cancers. Mol Biotechnol. [DOI: 10.1007/s12033-021-00443-3] [Reference Citation Analysis]
21 Zhu X, Yan M, Luo W, Liu W, Ren Y, Bei C, Tang G, Chen R, Tan S. Expression and clinical significance of PcG-associated protein RYBP in hepatocellular carcinoma. Oncol Lett 2017;13:141-50. [PMID: 28123534 DOI: 10.3892/ol.2016.5380] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
22 Yang N, Li S, Li G, Zhang S, Tang X, Ni S, Jian X, Xu C, Zhu J, Lu M. The role of extracellular vesicles in mediating progression, metastasis and potential treatment of hepatocellular carcinoma. Oncotarget. 2017;8:3683-3695. [PMID: 27713136 DOI: 10.18632/oncotarget.12465] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 12.3] [Reference Citation Analysis]
23 Wang L, Li N, Fan X, Wang X, Zhang X, Zhang K, Han Q, Lv Y, Liu Z. Circulating CTLA-4 levels and CTLA4 polymorphisms associate with disease condition and progression and hepatocellular carcinoma patients' survival in chronic hepatitis B virus infection. Int Immunopharmacol 2020;82:106377. [PMID: 32163858 DOI: 10.1016/j.intimp.2020.106377] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
24 Li W, Hao J, Zhang L, Cheng Z, Deng X, Shu G. Astragalin Reduces Hexokinase 2 through Increasing miR-125b to Inhibit the Proliferation of Hepatocellular Carcinoma Cells in Vitro and in Vivo. J Agric Food Chem 2017;65:5961-72. [PMID: 28654261 DOI: 10.1021/acs.jafc.7b02120] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 5.2] [Reference Citation Analysis]
25 Ma X, Wang J, Zhuang J, Ma X, Zheng N, Song Y, Xia W. P4HB modulates epithelial-mesenchymal transition and the β-catenin/Snail pathway influencing chemoresistance in liver cancer cells. Oncol Lett 2020;20:257-65. [PMID: 32565952 DOI: 10.3892/ol.2020.11569] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
26 Yang X, Guo X, Chen Y, Chen G, Ma Y, Huang K, Zhang Y, Zhao Q, Winkler CA, An P. Telomerase reverse transcriptase promoter mutations in hepatitis B virus-associated hepatocellular carcinoma. Oncotarget. 2016;7:27838-27847. [PMID: 27056898 DOI: 10.18632/oncotarget.8539] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
27 Wang L, Chen X, Wang L, Wang S, Li W, Liu Y, Zhang J. Knockdown of ST6Gal-I expression in human hepatocellular carcinoma cells inhibits their exosome-mediated proliferation- and migration-promoting effects. IUBMB Life 2021;73:1378-91. [PMID: 34559939 DOI: 10.1002/iub.2562] [Reference Citation Analysis]
28 Li M, Wang W, Jin R, Zhang T, Li N, Han Q, Wei P, Liu Z. Differential association of STAT3 and HK-II expression in hepatitis B virus- and hepatitis C virus-related hepatocellular carcinoma. J Med Virol 2016;88:1552-9. [PMID: 26889748 DOI: 10.1002/jmv.24498] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
29 Yang B, Wang S, Xie H, Wang C, Gao X, Rong Y, Liu Z, Lu Y. KIF18B promotes hepatocellular carcinoma progression through activating Wnt/β-catenin-signaling pathway. J Cell Physiol 2020;235:6507-14. [PMID: 32052444 DOI: 10.1002/jcp.29444] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
30 Zhang S, Xie C, Li H, Zhang K, Li J, Wang X, Yin Z. Ubiquitin-specific protease 11 serves as a marker of poor prognosis and promotes metastasis in hepatocellular carcinoma. Lab Invest 2018;98:883-94. [PMID: 29545598 DOI: 10.1038/s41374-018-0050-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
31 Song X, Zhang S, Tian R, Zheng C, Xu Y, Wang T, Bei C, Zhang H, He X, Zhu X, Tan S. Expression and clinical significance of CMTM1 in hepatocellular carcinoma. Open Med (Wars) 2021;16:217-23. [PMID: 33585698 DOI: 10.1515/med-2021-0221] [Reference Citation Analysis]
32 Guo X, Zhang S, Tan S, Bei C, Zhang H, Zhu X, Qiu X. Downregulated CMTM2 Poses Potential Clinical Significance in Hepatocellular Carcinoma. DNA Cell Biol 2020;39:683-9. [PMID: 31990600 DOI: 10.1089/dna.2019.5237] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
33 Hassanipour S, Vali M, Gaffari-Fam S, Nikbakht HA, Abdzadeh E, Joukar F, Pourshams A, Shafaghi A, Malakoutikhah M, Arab-Zozani M, Salehiniya H, Mansour-Ghanaei F. The survival rate of hepatocellular carcinoma in Asian countries: a systematic review and meta-analysis. EXCLI J 2020;19:108-30. [PMID: 32038120 DOI: 10.17179/excli2019-1842] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
34 Wong LL, Hernandez BY, Shvetsov YB, Kawano Y, Tang ZY, Ji JF. Liver resection for early hepatocellular cancer: Comparison of centers in 3 different countries. World J Hepatol 2016; 8(31): 1327-1335 [PMID: 27872684 DOI: 10.4254/wjh.v8.i31.1327] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
35 Shi Y, Zhai W, Wang B, Zhao D, Jin H, Wang Y, Zhang J, An H, Fu Z, Zhao K, Lu C. Genetic susceptibility of eight nonsynonymous polymorphisms in HLA-DRB1 gene to hepatocellular carcinoma in Han Chinese. Oncotarget 2016;7:80935-42. [PMID: 27821814 DOI: 10.18632/oncotarget.13111] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
36 Liu X, Qin S. Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Opportunities and Challenges. Oncologist 2019;24:S3-S10. [PMID: 30819826 DOI: 10.1634/theoncologist.2019-IO-S1-s01] [Cited by in Crossref: 24] [Cited by in F6Publishing: 34] [Article Influence: 12.0] [Reference Citation Analysis]
37 Zhu X, Qi G, Li C, Bei C, Tan C, Zhang Y, Shi W, Zeng W, Kong J, Fu Y, Tan S. Expression and Clinical Significance of CMTM6 in Hepatocellular Carcinoma. DNA Cell Biol 2019;38:193-7. [PMID: 30562063 DOI: 10.1089/dna.2018.4513] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 5.5] [Reference Citation Analysis]
38 Li Q, Li H, He C, Jing Z, Liu C, Xie J, Ma W, Deng H. The use of 5-fluorouracil-loaded nanobubbles combined with low-frequency ultrasound to treat hepatocellular carcinoma in nude mice. Eur J Med Res 2017;22:48. [PMID: 29162156 DOI: 10.1186/s40001-017-0291-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
39 Zhang X, Jin L, Tian Z, Wang J, Yang Y, Liu J, Chen Y, Hu C, Chen T, Zhao Y, He Y. Nitric oxide inhibits autophagy and promotes apoptosis in hepatocellular carcinoma. Cancer Sci. 2019;110:1054-1063. [PMID: 30657629 DOI: 10.1111/cas.13945] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 5.3] [Reference Citation Analysis]
40 Song X, Wang TX, Zhu XN, Tan SK. Immunological and prognostic significance of CBX2 expression in hepatocellular carcinoma. Shijie Huaren Xiaohua Zazhi 2021; 29(19): 1118-1129 [DOI: 10.11569/wcjd.v29.i19.1118] [Reference Citation Analysis]
41 Liu X, Tan XL, Xia M, Wu C, Song J, Wu JJ, Laurence A, Xie QG, Zhang MZ, Liang HF, Zhang BX, Chen XP. Loss of 11βHSD1 enhances glycolysis, facilitates intrahepatic metastasis, and indicates poor prognosis in hepatocellular carcinoma. Oncotarget 2016;7:2038-53. [PMID: 26700460 DOI: 10.18632/oncotarget.6661] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
42 Zhang S, Zhang K, Ji P, Zheng X, Jin J, Feng M, Liu P. GABPA predicts prognosis and inhibits metastasis of hepatocellular carcinoma. BMC Cancer 2017;17:380. [PMID: 28549418 DOI: 10.1186/s12885-017-3373-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
43 Wang D, Qi X, Liu F, Yang C, Jiang W, Wei X, Li X, Mi J, Tian G. A multicenter matched case-control analysis on seven polymorphisms from HMGB1 and RAGE genes in predicting hepatocellular carcinoma risk. Oncotarget 2017;8:50109-16. [PMID: 28187002 DOI: 10.18632/oncotarget.15202] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
44 Li Y, Liu M, Cui J, Yang K, Zhao L, Gong M, Wang Y, He Y, He T, Bi Y. Hepa1-6-FLuc cell line with the stable expression of firefly luciferase retains its primary properties with promising bioluminescence imaging ability. Oncol Lett 2018;15:6203-10. [PMID: 29616102 DOI: 10.3892/ol.2018.8132] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
45 Zhang Y, Zeng S, Ma J, Deng G, Qu Y, Guo C, Shen H. Nestin overexpression in hepatocellular carcinoma associates with epithelial-mesenchymal transition and chemoresistance. J Exp Clin Cancer Res 2016;35:111. [PMID: 27412382 DOI: 10.1186/s13046-016-0387-y] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
46 Li Z, Li N, Li F, Zhou Z, Sang J, Chen Y, Han Q, Lv Y, Liu Z. Immune checkpoint proteins PD-1 and TIM-3 are both highly expressed in liver tissues and correlate with their gene polymorphisms in patients with HBV-related hepatocellular carcinoma. Medicine (Baltimore). 2016;95:e5749. [PMID: 28033288 DOI: 10.1097/md.0000000000005749] [Cited by in Crossref: 42] [Cited by in F6Publishing: 34] [Article Influence: 8.4] [Reference Citation Analysis]
47 Li N, Zhou Z, Li F, Sang J, Han Q, Lv Y, Zhao W, Li C, Liu Z. Circulating soluble programmed death-1 levels may differentiate immune-tolerant phase from other phases and hepatocellular carcinoma from other clinical diseases in chronic hepatitis B virus infection. Oncotarget 2017;8:46020-33. [PMID: 28545019 DOI: 10.18632/oncotarget.17546] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
48 Zhang W, Liu Y, Fu Y, Han W, Xu H, Wen L, Deng Y, Liu K. Long non-coding RNA LINC00160 functions as a decoy of microRNA-132 to mediate autophagy and drug resistance in hepatocellular carcinoma via inhibition of PIK3R3. Cancer Lett. 2020;478:22-33. [PMID: 32067991 DOI: 10.1016/j.canlet.2020.02.014] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 9.5] [Reference Citation Analysis]
49 Wu J, Yang Y, Song J. Expression of SLC17A9 in hepatocellular carcinoma and its clinical significance. Oncol Lett 2020;20:182. [PMID: 32934749 DOI: 10.3892/ol.2020.12043] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
50 Zhu Z, Huang J, Liao M, Zeng Y. Treatment strategy for hepatocellular carcinoma in China: radiofrequency ablation versus liver resection. Jpn J Clin Oncol . [DOI: 10.1093/jjco/hyw134] [Cited by in Crossref: 5] [Cited by in F6Publishing: 22] [Article Influence: 0.8] [Reference Citation Analysis]